By Mill Chart
Last update: Jan 11, 2024
Our stock screener has singled out EXELIXIS INC (NASDAQ:EXEL) as an attractive growth opportunity. NASDAQ:EXEL is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:EXEL has achieved a 7 out of 10:
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:EXEL scores a 6 out of 10:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has received a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:EXEL, the assigned 8 is noteworthy for profitability:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Our latest full fundamental report of EXEL contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
EXELIXIS INC
NASDAQ:EXEL (4/19/2024, 7:00:02 PM)
After market: 22.52 0 (0%)22.52
+0.03 (+0.13%)
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
These stocks are worth buying in most months of the year.
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
You don't need to be a millionaire to get started. Investing on a budget can work, too.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.